D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report issued on Monday morning,Benzinga reports. They currently have a $21.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. HC Wainwright lifted their price objective on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Down 0.2 %

Shares of Trevi Therapeutics stock opened at $4.51 on Monday. The firm has a market capitalization of $346.67 million, a P/E ratio of -10.25 and a beta of 0.88. Trevi Therapeutics has a 52 week low of $2.30 and a 52 week high of $5.05. The company has a 50 day moving average price of $4.10 and a 200 day moving average price of $3.43.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. increased its holdings in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Woodline Partners LP increased its stake in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics in the fourth quarter valued at $58,000. Two Sigma Advisers LP purchased a new position in shares of Trevi Therapeutics during the 4th quarter worth $66,000. Finally, Two Sigma Investments LP purchased a new position in shares of Trevi Therapeutics during the 4th quarter worth $560,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.